Literature DB >> 27918194

First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report.

Daniel O'Connell1, Violet Shen1, William Loudon1, Daniela A Bota1.   

Abstract

We report the first case of a pediatric patient with glioblastoma (GBM; WHO grade IV astrocytoma) successfully treated with tumor treating fields (TTF). The patient was diagnosed with GBM when 13 years of age and progressed through surgical resection, radiotherapy and chemotherapy. Discrete tumor growth visualized on MRI with stable neurological examination was monitored for 6 months with subsequent stable disease observed radiographically and clinically for 7 months while adherent to Optune® (TTF). TTF thereby played a role in forestalling recurrent GBM growth in this young woman for 7 months without significant adverse effects. We propose that TTF therapy is a potential valuable treatment in this small, but sick, patient population.

Entities:  

Keywords:  CNS neoplasm; astrocytoma; bevacizumab; cisplatin; glioblastoma; glioma; pediatric; recurrence; temozolomide; tumor treating fields

Mesh:

Substances:

Year:  2016        PMID: 27918194      PMCID: PMC6027925          DOI: 10.2217/cns-2016-0018

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


  24 in total

1.  New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs.

Authors:  Dominik Sturm; Brent A Orr; Umut H Toprak; Volker Hovestadt; David T W Jones; David Capper; Martin Sill; Ivo Buchhalter; Paul A Northcott; Irina Leis; Marina Ryzhova; Christian Koelsche; Elke Pfaff; Sariah J Allen; Gnanaprakash Balasubramanian; Barbara C Worst; Kristian W Pajtler; Sebastian Brabetz; Pascal D Johann; Felix Sahm; Jüri Reimand; Alan Mackay; Diana M Carvalho; Marc Remke; Joanna J Phillips; Arie Perry; Cynthia Cowdrey; Rachid Drissi; Maryam Fouladi; Felice Giangaspero; Maria Łastowska; Wiesława Grajkowska; Wolfram Scheurlen; Torsten Pietsch; Christian Hagel; Johannes Gojo; Daniela Lötsch; Walter Berger; Irene Slavc; Christine Haberler; Anne Jouvet; Stefan Holm; Silvia Hofer; Marco Prinz; Catherine Keohane; Iris Fried; Christian Mawrin; David Scheie; Bret C Mobley; Matthew J Schniederjan; Mariarita Santi; Anna M Buccoliero; Sonika Dahiya; Christof M Kramm; André O von Bueren; Katja von Hoff; Stefan Rutkowski; Christel Herold-Mende; Michael C Frühwald; Till Milde; Martin Hasselblatt; Pieter Wesseling; Jochen Rößler; Ulrich Schüller; Martin Ebinger; Jens Schittenhelm; Stephan Frank; Rainer Grobholz; Istvan Vajtai; Volkmar Hans; Reinhard Schneppenheim; Karel Zitterbart; V Peter Collins; Eleonora Aronica; Pascale Varlet; Stephanie Puget; Christelle Dufour; Jacques Grill; Dominique Figarella-Branger; Marietta Wolter; Martin U Schuhmann; Tarek Shalaby; Michael Grotzer; Timothy van Meter; Camelia-Maria Monoranu; Jörg Felsberg; Guido Reifenberger; Matija Snuderl; Lynn Ann Forrester; Jan Koster; Rogier Versteeg; Richard Volckmann; Peter van Sluis; Stephan Wolf; Tom Mikkelsen; Amar Gajjar; Kenneth Aldape; Andrew S Moore; Michael D Taylor; Chris Jones; Nada Jabado; Matthias A Karajannis; Roland Eils; Matthias Schlesner; Peter Lichter; Andreas von Deimling; Stefan M Pfister; David W Ellison; Andrey Korshunov; Marcel Kool
Journal:  Cell       Date:  2016-02-25       Impact factor: 41.582

2.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Authors:  Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin
Journal:  Eur J Cancer       Date:  2012-05-18       Impact factor: 9.162

3.  Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.

Authors:  Kenneth J Cohen; Ian F Pollack; Tianni Zhou; Allen Buxton; Emiko J Holmes; Peter C Burger; Daniel J Brat; Marc K Rosenblum; Ronald L Hamilton; Robert S Lavey; Richard L Heideman
Journal:  Neuro Oncol       Date:  2011-03       Impact factor: 12.300

4.  The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group.

Authors:  R Sposto; I J Ertel; R D Jenkin; C P Boesel; J L Venes; J A Ortega; A E Evans; W Wara; D Hammond
Journal:  J Neurooncol       Date:  1989-07       Impact factor: 4.130

5.  Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases.

Authors:  Arie Perry; C Ryan Miller; Meena Gujrati; Bernd W Scheithauer; Sandro Casavilca Zambrano; Sarah C Jost; Ravi Raghavan; Jiang Qian; Elizabeth J Cochran; Jason T Huse; Eric C Holland; Peter C Burger; Marc K Rosenblum
Journal:  Brain Pathol       Date:  2008-04-29       Impact factor: 6.508

6.  Response patterns of recurrent glioblastomas treated with tumor-treating fields.

Authors:  Josef Vymazal; Eric T Wong
Journal:  Semin Oncol       Date:  2014-09-16       Impact factor: 4.929

7.  Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy.

Authors:  Andrew A Kanner; Eric T Wong; John L Villano; Zvi Ram
Journal:  Semin Oncol       Date:  2014-09-16       Impact factor: 4.929

8.  In Vivo c-Met Pathway Inhibition Depletes Human Glioma Xenografts of Tumor-Propagating Stem-Like Cells.

Authors:  Prakash Rath; Bachchu Lal; Olutobi Ajala; Yunqing Li; Shuli Xia; Jin Kim; John Laterra
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

Review 9.  Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review.

Authors:  Kimberly J Johnson; Jennifer Cullen; Jill S Barnholtz-Sloan; Quinn T Ostrom; Chelsea E Langer; Michelle C Turner; Roberta McKean-Cowdin; James L Fisher; Philip J Lupo; Sonia Partap; Judith A Schwartzbaum; Michael E Scheurer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-09-05       Impact factor: 4.254

10.  Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields).

Authors:  Eilon D Kirson; Rosa S Schneiderman; Vladimír Dbalý; Frantisek Tovarys; Josef Vymazal; Aviran Itzhaki; Daniel Mordechovich; Zoya Gurvich; Esther Shmueli; Dorit Goldsher; Yoram Wasserman; Yoram Palti
Journal:  BMC Med Phys       Date:  2009-01-08
View more
  6 in total

1.  Tumor treating fields in pediatric high-grade glioma.

Authors:  Adam L Green; Jean M Mulcahy Levy; Rajeev Vibhakar; Molly Hemenway; Jennifer Madden; Nicholas Foreman; Kathleen Dorris
Journal:  Childs Nerv Syst       Date:  2017-05-03       Impact factor: 1.475

2.  Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields.

Authors:  Edwin Chang; Christoph Pohling; Nooshin Beygui; Chirag B Patel; Jarrett Rosenberg; Dong Ho Ha; Sanjiv S Gambhir
Journal:  J Neurooncol       Date:  2017-07-05       Impact factor: 4.130

Review 3.  Tumor-Treating Fields Therapy for Pediatric Brain Tumors.

Authors:  Atsushi Makimoto; Ryo Nishikawa; Keita Terashima; Jun Kurihara; Hiroyuki Fujisaki; Satoshi Ihara; Yoshihiko Morikawa; Yuki Yuza
Journal:  Neurol Int       Date:  2021-04-08

4.  Safety of Tumor Treating Fields (TTFields) therapy in pediatric patients with malignant brain tumors: Post-marketing surveillance data.

Authors:  Stewart Goldman; Ashley Margol; Eugene I Hwang; Kazuhiro Tanaka; Bogdana Suchorska; John R Crawford; Santosh Kesari
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

5.  Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report.

Authors:  Hanna Gött; Silke Kiez; Hildegard Dohmen; Malgorzata Kolodziej; Marco Stein
Journal:  Childs Nerv Syst       Date:  2022-02-18       Impact factor: 1.532

Review 6.  Tumour treating fields therapy for glioblastoma: current advances and future directions.

Authors:  Ola Rominiyi; Aurelie Vanderlinden; Susan Jane Clenton; Caroline Bridgewater; Yahia Al-Tamimi; Spencer James Collis
Journal:  Br J Cancer       Date:  2020-11-04       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.